Tumour growth inhibition and anti-metastatic activity of a mutated furin-resistant Semaphorin 3E isoform

Andrea Casazza, Boaz Kigel, Federica Maione, Lorena Capparuccia, Ofra Kessler, Enrico Giraudo, Massimiliano Mazzone, Gera Neufeld, Luca Tamagnone

Research output: Contribution to journalArticle

58 Citations (Scopus)

Abstract

Secreted Semaphorin 3E (Sema3E) promotes cancer cell invasiveness and metastatic spreading. The pro-metastatic activity of Sema3E is due to its proteolytic fragment p61, capable of transactivating the oncogenic tyrosine kinase ErbB2 that associates with the Sema3E receptor PlexinD1 in cancer cells. Here, we show that a mutated, uncleavable variant of Sema3E (Uncl-Sema3E) binds to PlexinD1 like p61-Sema3E, but does not promote the association of PlexinD1 with ErbB2 nor activates the ensuing signalling cascade leading to metastatic spreading. Furthermore, Uncl-Sema3E competes with endogenous p61-Sema3E produced by tumour cells, thereby hampering their metastatic ability. Uncl-Sema3E also acts independently as a potent anti-angiogenic factor. It activates a PlexinD1-mediated signalling cascade in endothelial cells that leads to the inhibition of adhesion to extracellular matrix, directional migration and cell survival. The putative therapeutic potential of Uncl-Sema3E was validated in multiple orthotopic or spontaneous tumour models in vivo, where either local or systemic delivery of Uncl-Sema3E-reduced angiogenesis, growth and metastasis, even in the case of tumours refractory to treatment with a soluble vascular endothelial growth factor trap. In summary, we conclude that Uncl-Sema3E is a novel inhibitor of tumour angiogenesis and growth that concomitantly hampers metastatic spreading.

Original languageEnglish
Pages (from-to)234-250
Number of pages17
JournalEMBO Molecular Medicine
Volume4
Issue number3
DOIs
Publication statusPublished - Mar 2012

Fingerprint

Semaphorins
Furin
Protein Isoforms
Growth
Neoplasms
Growth Inhibitors
Angiogenesis Inhibitors
Angiogenesis Inducing Agents
Protein-Tyrosine Kinases
Vascular Endothelial Growth Factor A
Extracellular Matrix
Cell Survival
Endothelial Cells
Neoplasm Metastasis

Keywords

  • Angiogenesis
  • Metastasis
  • Plexin
  • Semaphorin
  • Tumour growth

ASJC Scopus subject areas

  • Molecular Medicine

Cite this

Tumour growth inhibition and anti-metastatic activity of a mutated furin-resistant Semaphorin 3E isoform. / Casazza, Andrea; Kigel, Boaz; Maione, Federica; Capparuccia, Lorena; Kessler, Ofra; Giraudo, Enrico; Mazzone, Massimiliano; Neufeld, Gera; Tamagnone, Luca.

In: EMBO Molecular Medicine, Vol. 4, No. 3, 03.2012, p. 234-250.

Research output: Contribution to journalArticle

Casazza, Andrea ; Kigel, Boaz ; Maione, Federica ; Capparuccia, Lorena ; Kessler, Ofra ; Giraudo, Enrico ; Mazzone, Massimiliano ; Neufeld, Gera ; Tamagnone, Luca. / Tumour growth inhibition and anti-metastatic activity of a mutated furin-resistant Semaphorin 3E isoform. In: EMBO Molecular Medicine. 2012 ; Vol. 4, No. 3. pp. 234-250.
@article{c864133a86964144898dd426c9105b73,
title = "Tumour growth inhibition and anti-metastatic activity of a mutated furin-resistant Semaphorin 3E isoform",
abstract = "Secreted Semaphorin 3E (Sema3E) promotes cancer cell invasiveness and metastatic spreading. The pro-metastatic activity of Sema3E is due to its proteolytic fragment p61, capable of transactivating the oncogenic tyrosine kinase ErbB2 that associates with the Sema3E receptor PlexinD1 in cancer cells. Here, we show that a mutated, uncleavable variant of Sema3E (Uncl-Sema3E) binds to PlexinD1 like p61-Sema3E, but does not promote the association of PlexinD1 with ErbB2 nor activates the ensuing signalling cascade leading to metastatic spreading. Furthermore, Uncl-Sema3E competes with endogenous p61-Sema3E produced by tumour cells, thereby hampering their metastatic ability. Uncl-Sema3E also acts independently as a potent anti-angiogenic factor. It activates a PlexinD1-mediated signalling cascade in endothelial cells that leads to the inhibition of adhesion to extracellular matrix, directional migration and cell survival. The putative therapeutic potential of Uncl-Sema3E was validated in multiple orthotopic or spontaneous tumour models in vivo, where either local or systemic delivery of Uncl-Sema3E-reduced angiogenesis, growth and metastasis, even in the case of tumours refractory to treatment with a soluble vascular endothelial growth factor trap. In summary, we conclude that Uncl-Sema3E is a novel inhibitor of tumour angiogenesis and growth that concomitantly hampers metastatic spreading.",
keywords = "Angiogenesis, Metastasis, Plexin, Semaphorin, Tumour growth",
author = "Andrea Casazza and Boaz Kigel and Federica Maione and Lorena Capparuccia and Ofra Kessler and Enrico Giraudo and Massimiliano Mazzone and Gera Neufeld and Luca Tamagnone",
year = "2012",
month = "3",
doi = "10.1002/emmm.201100205",
language = "English",
volume = "4",
pages = "234--250",
journal = "EMBO Molecular Medicine",
issn = "1757-4676",
publisher = "Wiley-Blackwell",
number = "3",

}

TY - JOUR

T1 - Tumour growth inhibition and anti-metastatic activity of a mutated furin-resistant Semaphorin 3E isoform

AU - Casazza, Andrea

AU - Kigel, Boaz

AU - Maione, Federica

AU - Capparuccia, Lorena

AU - Kessler, Ofra

AU - Giraudo, Enrico

AU - Mazzone, Massimiliano

AU - Neufeld, Gera

AU - Tamagnone, Luca

PY - 2012/3

Y1 - 2012/3

N2 - Secreted Semaphorin 3E (Sema3E) promotes cancer cell invasiveness and metastatic spreading. The pro-metastatic activity of Sema3E is due to its proteolytic fragment p61, capable of transactivating the oncogenic tyrosine kinase ErbB2 that associates with the Sema3E receptor PlexinD1 in cancer cells. Here, we show that a mutated, uncleavable variant of Sema3E (Uncl-Sema3E) binds to PlexinD1 like p61-Sema3E, but does not promote the association of PlexinD1 with ErbB2 nor activates the ensuing signalling cascade leading to metastatic spreading. Furthermore, Uncl-Sema3E competes with endogenous p61-Sema3E produced by tumour cells, thereby hampering their metastatic ability. Uncl-Sema3E also acts independently as a potent anti-angiogenic factor. It activates a PlexinD1-mediated signalling cascade in endothelial cells that leads to the inhibition of adhesion to extracellular matrix, directional migration and cell survival. The putative therapeutic potential of Uncl-Sema3E was validated in multiple orthotopic or spontaneous tumour models in vivo, where either local or systemic delivery of Uncl-Sema3E-reduced angiogenesis, growth and metastasis, even in the case of tumours refractory to treatment with a soluble vascular endothelial growth factor trap. In summary, we conclude that Uncl-Sema3E is a novel inhibitor of tumour angiogenesis and growth that concomitantly hampers metastatic spreading.

AB - Secreted Semaphorin 3E (Sema3E) promotes cancer cell invasiveness and metastatic spreading. The pro-metastatic activity of Sema3E is due to its proteolytic fragment p61, capable of transactivating the oncogenic tyrosine kinase ErbB2 that associates with the Sema3E receptor PlexinD1 in cancer cells. Here, we show that a mutated, uncleavable variant of Sema3E (Uncl-Sema3E) binds to PlexinD1 like p61-Sema3E, but does not promote the association of PlexinD1 with ErbB2 nor activates the ensuing signalling cascade leading to metastatic spreading. Furthermore, Uncl-Sema3E competes with endogenous p61-Sema3E produced by tumour cells, thereby hampering their metastatic ability. Uncl-Sema3E also acts independently as a potent anti-angiogenic factor. It activates a PlexinD1-mediated signalling cascade in endothelial cells that leads to the inhibition of adhesion to extracellular matrix, directional migration and cell survival. The putative therapeutic potential of Uncl-Sema3E was validated in multiple orthotopic or spontaneous tumour models in vivo, where either local or systemic delivery of Uncl-Sema3E-reduced angiogenesis, growth and metastasis, even in the case of tumours refractory to treatment with a soluble vascular endothelial growth factor trap. In summary, we conclude that Uncl-Sema3E is a novel inhibitor of tumour angiogenesis and growth that concomitantly hampers metastatic spreading.

KW - Angiogenesis

KW - Metastasis

KW - Plexin

KW - Semaphorin

KW - Tumour growth

UR - http://www.scopus.com/inward/record.url?scp=84858114637&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84858114637&partnerID=8YFLogxK

U2 - 10.1002/emmm.201100205

DO - 10.1002/emmm.201100205

M3 - Article

C2 - 22247010

AN - SCOPUS:84858114637

VL - 4

SP - 234

EP - 250

JO - EMBO Molecular Medicine

JF - EMBO Molecular Medicine

SN - 1757-4676

IS - 3

ER -